Vivace Therapeutics News and Activities

Vivace Therapeutics is owned by Mission BioCapital. Mission BioCapital has a direct presence in 2 countries.

Mission BioCapital has 20 subsidiaries including Alessa Therapeutics, Avvio Medical and Avvio Medical AMEA.

They are in:

• Biotechnology76%
• Healthcare10%
• Other14%

Acquisition, funding and merger involving Mission BioCapital.

• Mission BioCapital has just announced a $134 Million fundraising (posted on September 28 2025).

View the org chart displaying its 10 main executives

Most searched biographies at Vivace Therapeutics

• Craig Gibbs, Chief Executive Officer
• Tim Shannon, Director
• Norman Zhou, Director

Popular executive movements at Vivace Therapeutics

• Craig Gibbs has joined the company as Chief Executive Officer  (posted on May 22 2026).

Create your alert
to follow the executive moves at Vivace Therapeutics.

Mission BioCapital has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Vivace Therapeutics

• VT3989, Vivace Therapeutics' Best-in-Class, Hippo Pathway-Targeting Therapy, Demonstrates Promising Antitumor Activity in Refractory Mesothelioma
• New Clinical Data for Vivace Therapeutics' Best-in-Class, Hippo Pathway-Targeting Therapy to be Presented in Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2025
• Vivace Therapeutics' VT3989 Granted Fast Track Designation by the U.S. Food and Drug Administration for the Treatment of Mesothelioma
• Vivace Therapeutics Announces Receipt of Orphan Drug Designation for VT3989 for Treatment of Mesothelioma
• Vivace Therapeutics Raises $35 Million in Series D Financing to Support Clinical Development of First-in-Class Cancer Drug Targeting the Hippo Pathway
• Vivace Therapeutics Presents New Preclinical Data Highlighting Strong Synergistic Activity for Combination of VT3989 and Osimertinib at American Association for Cancer Research (AACR) Annual Meeting 2022
• Researchers Report Clinical Proof-of-Concept Data for Vivace Therapeutics' VT3989, a First for a Cancer Drug Targeting the Hippo Pathway, in Oral Presentation at AACR 2023
• Vivace Therapeutics to Unveil First Clinical Data for a Cancer Drug Targeting the Hippo Pathway
• Home | Vivace
• https://vivacetherapeutics.com/wp-content/uploads/Vivace-press-release-20201211-FINAL.pdf
• View more press releases Close

Social media about Vivace Therapeutics

• Vivace Therapeutics on Wikipedia, Google News & Yahoo Finance
• Vivace Therapeutics on LinkedIn, X (Twitter) & YouTube